Roche Deepens Its Bet on Hansoh’s ADC Engine With a $15 Billion Pact
Roche has returned to Hansoh Pharmaceutical with a deal that places antibody-drug conjugates at the center of its next wave of oncology partnering. One year after the companies first joined forces around a CDH17-targeted ADC, the new agreement spans a broad portfolio of programs and gives Roche a larger position in Hansoh’s preclinical pipeline, while preserving Hansoh’s role in early development.
The structure is familiar in one respect and much bigger in another. Hansoh will advance the partnered ADC programs through phase 1 testing in China before transferring worldwide development rights to Roche outside Greater China. In exchange, the Jiangsu-based biopharma receives $400 million upfront, followed by $110 million on the first anniversary of the deal, with potential development, regulatory, and commercialization milestones that could bring the total value to as much as $15 billion, plus tiered royalties if products reach the market.
For a field as capital-intensive as oncology biologics, the handoff after phase 1 is strategically important. Early human testing is often where ADCs reveal whether their payload, linker chemistry, and target biology can hold together under clinical pressure. If a molecule survives that stage, a global pharma partner can bring the manufacturing scale, regulatory bandwidth, and commercial reach needed to carry it through late development. Roche is buying access to that upstream engine before the rest of the market can fully price it in.
A Broader ADC Portfolio and a Shared Development Path
Hansoh said the collaboration includes two ADCs already in preclinical development, alongside multiple additional programs built around targets proposed by Roche and enabled by Hansoh’s ADC platform. The company also left room for an unusual option: Hansoh can choose to contribute to global development of two programs from the collaboration and, if it does, gain incremental upside from commercialization of those assets.
That clause matters because it keeps Hansoh closer to the value it helps create. Rather than stopping at a clean ex-China license, the arrangement allows the Chinese company to retain optional strategic participation in assets that may prove especially compelling once early clinical data arrive. For Roche, the setup broadens its ADC portfolio without requiring the company to build every program from scratch.
The language around the collaboration reflects how central ADC innovation has become in oncology partnering. These molecules are designed to combine a target-specific antibody with a cytotoxic payload, aiming to concentrate drug delivery in tumor tissue while limiting exposure in normal tissue. When the target biology is strong and the linker chemistry is stable enough to protect the payload until it reaches the cancer cell, the format can produce meaningful antitumor activity in settings where conventional chemotherapy has already been exhausted.
One sentence captures the commercial reality: Roche wants more shots on goal in a therapeutic class still full of unmet need.
Roche’s Second Hansoh Deal Follows a CDH17 Program Already in Phase 1
The new pact builds on a previous transaction from a year ago, when Roche paid Hansoh $80 million upfront and committed up to $1.45 billion in biobucks for the ex-China rights to HS-20110, a CDH17-targeted ADC. That asset was already in phase 1 testing in China and the U.S. at the time, with colorectal cancer and other solid tumors among the intended indications.
The earlier deal gave Roche an immediate foothold in an ADC space increasingly shaped by target selection. CDH17 has drawn attention because of its potential relevance in gastrointestinal malignancies, a domain where effective targeted options remain limited for many patients. Roche’s decision to return to Hansoh suggests the first collaboration did more than secure a single asset; it likely signaled confidence in the platform behind it.
Boris Zaïtra, who leads corporate business development at Roche, framed the expansion as a step in the company’s broader ADC vision. The phrasing is unsurprising, but the strategic message is clear: Roche is trying to build depth in a category where the most valuable assets may come from repeat access to proven biology and platform expertise, not one-off acquisitions.
China’s ADC Ambition Is Drawing More Global Capital
Hansoh has become a recurring counterpart for large Western drugmakers seeking exposure to China’s fast-moving innovation base. The company has already partnered with Merck & Co. and Regeneron, and its pipeline now includes more than 40 innovative medicine candidates being assessed across more than 70 clinical trials. R&D spending rose 20.7% to 1.7 billion Chinese yuan, or $253 million, in the first half of the year, indicates how aggressively the company is backing its own discovery engine.
The broader setting helps explain why global pharma is returning to Chinese biotechs for ADC access. China has moved from a source of low-cost development capacity to a genuine originator of differentiated drug programs. Hansoh has described the sector as shifting from a follower role to a frontrunner role, and the recent pace of international licensing deals supports that assessment.
Competition is also intensifying around the same drug class. GSK has already reported clinical progress with ADCs aimed at B7-H3 and B7-H4, including a B7-H3 program that recently posted a median overall survival of 18.5 months in phase 3 and a 61% overall response rate in phase 1b. Those results raise the bar for any newcomer in the field and explain why big pharma is paying such steep prices for early access to promising programs.
The stakes are high because ADCs can fail in several ways at once: by missing the target, by releasing payload too early, by failing to penetrate tumor tissue, or by producing toxicity that limits dosing. A platform that can repeatedly generate credible candidates is rare, and rarity is what turns a partnering discussion into a multibillion-dollar transaction.
Roche’s renewed commitment to Hansoh says less about a single molecule than about the company’s confidence in a repeatable discovery engine. The open question is how many of these partnered programs can clear phase 1, maintain tolerability, and show enough tumor control to justify global development in a field where expectations are already rising fast.